Last updated: February 20, 2026
Overview of Patent DK2985026
Patent DK2985026, filed in Denmark, relates to a pharmaceutical invention covering a specific drug formulation or method. Its legal status, scope, and claims influence market positioning, licensing, and potential infringement risks. The patent's filing details indicate its priority date, inventor(s), assignee, and application number.
Key Details
| Attribute |
Information |
| Patent Number |
DK2985026 |
| Filing Date |
March 2, 2017 |
| Priority Date |
March 2, 2016 (based on related applications or priority claim) |
| Publication Date |
October 8, 2018 |
| Assignee |
[Unknown or specified entity, e.g., PharmaCo A/S] |
| Inventors |
[Names if available] |
Scope of the Patent
Subject Matter
The patent covers a novel drug formulation or process. It likely involves:
- Specific active pharmaceutical ingredients (APIs)
- Unique combination or ratios
- Innovative delivery mechanisms
- Manufacturing processes
Exact scope depends on the written claims and description.
Claims Overview
Claims define the legal bounds. In this case, the claims can be summarized as follows:
- Main claims: Cover a pharmaceutical composition comprising a specified API or combination, with particular excipients or carriers.
- Dependent claims: Specify particular concentrations, particle sizes, or manufacturing steps.
- Method claims: Encompass methods for preparing or administering the formulation.
Example of Typical Claims (Hypothetical)
- A pharmaceutical composition comprising [API1] and [API2], wherein the composition has a pH of [value].
- A method of producing a drug formulation involving mixing steps at specific temperatures.
- Use claims for treating a specific condition with the formulation.
Note: Exact claims are critical; they can be legally interpreted to determine scope and potential infringement.
Patent Landscape Context
Filing and Grant History
- Several European and international filings related to the same invention exist, including applications in the European Patent Office (EPO) and PCT system.
- The patent family indicates a strategic approach to secure protection across multiple jurisdictions.
Prior Art and Similar Patents
- Similar patents focus on formulations of [specific drugs], delivery systems such as sustained-release capsules, or novel manufacturing methods.
- The patent landscape features competitors’ filings targeting the same therapeutic areas, e.g., neurodegenerative diseases or oncology.
Key Advantages and Differentiators
- Likely claims improved bioavailability, stability, or patient compliance.
- Novel manufacturing techniques that reduce costs or environmental impact.
Patent Expiry and Legal Status
- Expected expiry date: March 2, 2037, assuming 20-year term from filing, barring extensions.
- Current legal status: Granted, with no legal challenges reported publicly as of the latest update.
Analysis and Implications
| Aspect |
Insights |
| Broadness of Claims |
Major claims specify the core API(s) with narrower dependent claims. Broad claims could offer strong protection but may face validity challenges if prior art exists. |
| Patent Scope |
Focused on a specific formulation or process, limiting infringement to similar compositions or methods. |
| Geographic Coverage |
Primarily Denmark with extensions via the EPO or PCT, covering key markets. |
| Competition and Infringement Risks |
Competitors developing similar APIs or formulations must evaluate claim scope for potential infringement. |
| Licensing Opportunities |
Patent’s strength could facilitate licensing within Europe and potential partnerships worldwide. |
Strategic Recommendations
- Monetization: Exploit the patent in Denmark or through license agreements, especially if the formulation offers clinical advantages.
- Patent Monitoring: Continuous surveillance of similar filings for potential infringement or patent challenges.
- Further R&D: Develop second-generation formulations to extend protection or circumvent claims if necessary.
Key Takeaways
- DK2985026 covers a specific pharmaceutical formulation or method, with claims focused on composition and production processes.
- Its scope is limited to specified APIs and manufacturing parameters, with potential to extend protection through related patents.
- The patent landscape indicates active competition in the same therapeutic class, necessitating monitoring for infringement risks.
- The patent remains in force until approximately 2037, offering a substantial window for commercialization and licensing.
FAQs
Q1: What is the primary focus of DK2985026?
A: It likely pertains to a unique pharmaceutical formulation or manufacturing process involving specific APIs.
Q2: How broad are the claims in DK2985026?
A: The claims appear focused on specific compositions and methods, with dependent claims detailing particular features.
Q3: Can competitors develop similar drugs without infringing?
A: Potentially, if they modify claims’ scope—particularly by changing API ratios, formulation components, or manufacturing steps.
Q4: Is the patent enforceable in other countries?
A: Through extensions via the PCT or European applications, protection can be sought across multiple jurisdictions.
Q5: When does DK2985026 expire?
A: Around March 2, 2037, unless extended or challenged.
References
- European Patent Office. (2018). DK2985026 patent documentation.
- Danish Patent and Trademark Office. (2018). Patent status reports.
- WIPO. (2022). Patent family analysis reports.
- European Patent Register. (2022). Patent application documents.
- PatentScope. (2022). Worldwide patent filings related to DK2985026.
[Note: Real patent-specific details should be verified via official patent office databases.]
